Aclarion's Nociscan AI Advances Understanding of Modic Changes in Chronic Low Back Pain
TL;DR
Aclarion's Nociscan solution provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
MRS measurement of intradiscal propionic acid can clarify Modic changes (MC) etiology and help stratify MC patients to potentially inform better treatment decisions for cLBP patients.
Aclarion's focus is to provide physicians with new noninvasive information they can use to help make better decisions about patient care.
The results challenge the notion that the disc environment is sterile, and PA levels may be useful for understanding why some patients with MC improve or respond to treatment while others do not.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc. has announced that its Nociscan solution has played a crucial role in advancing the understanding of Modic changes (MC) in patients with chronic low back pain (cLBP). The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024 in Milan, Italy, utilized Nociscan's AI-driven technology to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, challenges the long-held belief that the disc environment is sterile. Dr. Aaron Fields, leading the study, emphasized that PA levels could be instrumental in understanding why some patients with MC improve or respond to treatment while others do not. This finding has significant implications for the treatment of cLBP, a condition affecting 266 million people globally.
Aclarion's Nociscan solution stands out as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. By objectively quantifying chemical biomarkers associated with disc pain, Nociscan provides critical insights into the location of a patient's low back pain when used in conjunction with other diagnostic tools.
The study's findings open up new possibilities for personalized treatment approaches. The ability to measure PA levels noninvasively could potentially lead to more targeted treatments, such as the use of antibiotics as a first line of treatment for cLBP patients with high levels of PA. This approach could significantly improve clinical outcomes and revolutionize the way chronic low back pain is diagnosed and treated.
Ryan Bond, Chief Strategy Officer at Aclarion, highlighted the importance of providing physicians with new noninvasive information to make better decisions about patient care. The company's focus on identifying biomarkers through Nociscan technology is paving the way for more personalized treatment plans aimed at improving patient outcomes.
As research in this area continues to evolve, the implications for the healthcare industry and patients suffering from chronic low back pain are substantial. The potential for more accurate diagnoses and tailored treatment strategies could lead to improved patient care, reduced healthcare costs, and a better quality of life for millions of people worldwide affected by this debilitating condition.
Curated from NewMediaWire
